Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12798111 | 1.00 | SLC6A4 (0.39) | SLC6A4CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL12966711 | 1.00 | SLC6A4 (0.39) | SLC6A4CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL13725538 | 0.85 | SLC6A4 (0.42) | SLC6A4CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL10005572 | 0.85 | SLC6A4 (0.42) | SLC6A4CACNA1FCHRM2CHRM1ADRA2B | |
| SCHEMBL29444030 | 0.78 | SLC6A4 (0.35) | SLC6A4 | |
| SCHEMBL14962046 | 0.76 | SLC6A4 (0.43) | SLC6A4 | |
| SCHEMBL25055337 | 0.73 | PIK3CD (0.30) | — | |
| SCHEMBL24092098 | 0.73 | SLC6A4 (0.37) | SLC6A4 | |
| SCHEMBL24092088 | 0.73 | SLC6A4 (0.37) | SLC6A4 | |
| SCHEMBL24700037 | 0.71 | CACNA1F (0.30) | SLC6A4CACNA1FCHRM2CHRM1ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793893-B2 | Compounds comprising conductive oligomers, materials formed therefrom, and methods of making and using same | THE PENN STATE RESEARCH FOUNDATION (PA) | 2023-10-24 | — | — | US | disclosed |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | OREGON STATE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220009944-A1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2022-01-13 | — | — | US | disclosed |
| US-11032855-B2 | System and method for communication of analyte data | DEXCOM, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-22 | — | — | US | disclosed |
| US-20080311079-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080311079-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080125376-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-29 | — | — | US | disclosed |
| US-7378422-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-05-27 | — | — | US | disclosed |
| US-7365092-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-29 | — | — | US | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311079-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | SLC6A4 1616/4885CACNA1F 4842/4885CHRM2 4880/4885 |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | CRHR1, CRHR2, SCTR | SLC6A4 159/4885CACNA1F 2117/4885CHRM2 297/4885 |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | SLC6A4 4594/4885CACNA1F 4759/4885CHRM2 4883/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | SLC6A4 4727/4885CACNA1F 3867/4885CHRM2 4875/4885 |
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | SLC6A4 1149/4885CACNA1F 4725/4885CHRM2 4868/4885 |
| US-20220009944-A1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | SLC6A2, NAPRT, SLC6A3 | SLC6A4 30/4885CACNA1F 1216/4885CHRM2 1449/4885 |
| US-11793893-B2 | Compounds comprising conductive oligomers, materials formed therefrom, and methods of making and using same | PICALM, ILK, GJB2 | SLC6A4 3218/4885CACNA1F 388/4885CHRM2 358/4885 |
| US-20080125376-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | SLC6A4 1120/4885CACNA1F 4711/4885CHRM2 4866/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | SLC6A4 4642/4885CACNA1F 4786/4885CHRM2 4839/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | SLC6A4 4873/4885CACNA1F 4562/4885CHRM2 4806/4885 |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | SLC6A4 448/4885CACNA1F 4533/4885CHRM2 4872/4885 |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | SLC6A2, NAPRT, SLC6A3 | SLC6A4 30/4885CACNA1F 1216/4885CHRM2 1449/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | SLC6A4 4401/4885CACNA1F 4282/4885CHRM2 3989/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | SLC6A4 4734/4885CACNA1F 3870/4885CHRM2 4876/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | SLC6A4 4873/4885CACNA1F 4562/4885CHRM2 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.